MXPA05006034A - Proteina de duplicacion. - Google Patents

Proteina de duplicacion.

Info

Publication number
MXPA05006034A
MXPA05006034A MXPA05006034A MXPA05006034A MXPA05006034A MX PA05006034 A MXPA05006034 A MX PA05006034A MX PA05006034 A MXPA05006034 A MX PA05006034A MX PA05006034 A MXPA05006034 A MX PA05006034A MX PA05006034 A MXPA05006034 A MX PA05006034A
Authority
MX
Mexico
Prior art keywords
replication protein
modulate
activity
relates
dna replication
Prior art date
Application number
MXPA05006034A
Other languages
English (en)
Inventor
Coverley Dawn
Original Assignee
Yorkshire Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yorkshire Cancer Res filed Critical Yorkshire Cancer Res
Publication of MXPA05006034A publication Critical patent/MXPA05006034A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se refiere a un metodo de examen para identificar agentes que modulan la actividad de una proteina de duplicacion de ADN, como un blanco de intervencion para la terapia del cancer, e incluye agentes que modulan dicha actividad; la invencion tambien se refiere al uso de la proteina de duplicacion de ADN y sus transcritos de ARN para pronosticar y diagnosticar una enfermedad proliferativa, por ejemplo el cancer.
MXPA05006034A 2002-12-05 2003-12-05 Proteina de duplicacion. MXPA05006034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228337.2A GB0228337D0 (en) 2002-12-05 2002-12-05 Replication protein
PCT/GB2003/005334 WO2004051269A2 (en) 2002-12-05 2003-12-05 Ciz1 replication protein

Publications (1)

Publication Number Publication Date
MXPA05006034A true MXPA05006034A (es) 2006-01-27

Family

ID=9949091

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006034A MXPA05006034A (es) 2002-12-05 2003-12-05 Proteina de duplicacion.

Country Status (12)

Country Link
US (3) US7833702B2 (es)
EP (2) EP2316966B1 (es)
JP (1) JP2006508659A (es)
CN (1) CN1720442A (es)
AT (1) ATE534902T1 (es)
AU (1) AU2003290240B2 (es)
CA (1) CA2507403C (es)
ES (2) ES2556704T3 (es)
GB (1) GB0228337D0 (es)
HU (1) HUE028241T2 (es)
MX (1) MXPA05006034A (es)
WO (1) WO2004051269A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
JP2009159869A (ja) 2007-12-28 2009-07-23 Univ Of Occupational & Environmental Health Japan 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
GB0901837D0 (en) * 2009-02-05 2009-03-11 Cizzle Biotechnology Ltd Cancer diagnosis and treatment
AU2011287430A1 (en) * 2010-08-04 2013-03-21 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of cancer
CN103421886B (zh) * 2012-05-21 2018-10-12 上海吉凯基因化学技术有限公司 Ciz1基因的用途及其相关药物
WO2017057567A1 (ja) * 2015-10-02 2017-04-06 株式会社村田製作所 電力増幅モジュール、フロントエンド回路および通信装置
GB201518466D0 (en) 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
WO2017126615A1 (ja) * 2016-01-19 2017-07-27 国立大学法人 東京大学 経時変化の情報を基に細胞を回収する方法およびシステム
CN109694411A (zh) * 2017-10-21 2019-04-30 蔡胜和 抗-ciz1抗体
WO2019079914A1 (zh) * 2017-10-23 2019-05-02 蔡胜和 抗-ciz1抗体
CN108796083B (zh) * 2018-06-25 2021-03-19 山东大学 Ciz1作为诊治舌体血管瘤的分子标记物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001072777A2 (en) 2000-03-13 2001-10-04 Incyte Genomics, Inc. Human transcription factors
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
NL2003837C2 (en) * 2008-11-19 2010-08-05 Rijk Zwaan Zaadteelt En Zaadhandel Bv Resistance to post harvest deterioration in cucumber.

Also Published As

Publication number Publication date
ES2556704T3 (es) 2016-01-19
WO2004051269A3 (en) 2004-10-28
US20110070591A1 (en) 2011-03-24
EP2316966B1 (en) 2015-09-16
AU2003290240B2 (en) 2012-06-14
AU2003290240A1 (en) 2004-06-23
EP1570268B1 (en) 2011-11-23
HUE028241T2 (en) 2016-12-28
EP1570268A2 (en) 2005-09-07
JP2006508659A (ja) 2006-03-16
WO2004051269A2 (en) 2004-06-17
CA2507403C (en) 2015-01-20
ATE534902T1 (de) 2011-12-15
US20060155113A1 (en) 2006-07-13
CN1720442A (zh) 2006-01-11
CA2507403A1 (en) 2004-06-17
EP2316966A1 (en) 2011-05-04
US7833702B2 (en) 2010-11-16
ES2376746T3 (es) 2012-03-16
GB0228337D0 (en) 2003-01-08
US9541555B2 (en) 2017-01-10
US20160011200A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
MXPA05012832A (es) Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4.
WO2003087831A3 (en) Proteins involved in breast cancer
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
MXPA05006034A (es) Proteina de duplicacion.
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006113579A3 (en) Tumor inhibition by modulating sprouty expression or activity
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
DE50009365D1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
DK1618195T3 (da) Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)
WO2006029406A3 (en) Methods for treating bone tumors using bone morphogenic proteins

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration